Market news

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2026 (New York, New York)Thursday, September 10, 2026, at 2:10 p.m. ET, fireside chat Morgan Stanley 24th Annual Global Healthcare Conference (N

Detailed price information for Biomarin Pharmaceuticals (BMRN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Alector Inc (ALEC-Q) from The Globe and Mail including charting and trades.

Detailed price information for Xenon Pharmaceuticals Inc (XENE-Q) from The Globe and Mail including charting and trades.

GSK-backed Ris-Rez posts positive Phase 3 survival data in small-cell lung cancer as the company moves to end its collaboration with Alector.

Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.

July 8 (Reuters) - Alector said on Wednesday that GSK had terminated their neuroscience collaboration agreement covering two experimental antibody drugs after both the drug candidates suffered